PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
Helps investors judge whether earnings growth is driven by sustainable operations or temporary factors. Consistent, organic income expansion can justify a higher intrinsic value for patient, long-term investors.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
6.82%
R&D growth 1.1-1.25x CRVO's 5.59%. Bill Ackman would demand evidence of superior returns.
-13.19%
G&A reduction while CRVO shows 37.03% growth. Joel Greenblatt would examine efficiency advantage.
No Data
No Data available this quarter, please select a different quarter.
-1.40%
Other expenses reduction while CRVO shows 100.00% growth. Joel Greenblatt would examine efficiency.
-2.45%
Operating expenses reduction while CRVO shows 251.41% growth. Joel Greenblatt would examine advantage.
-2.45%
Total costs reduction while CRVO shows 15.98% growth. Joel Greenblatt would examine advantage.
No Data
No Data available this quarter, please select a different quarter.
-1.40%
Both companies reducing D&A. Martin Whitman would check industry patterns.
-13.13%
Both companies show EBITDA decline. Martin Whitman would check industry conditions.
No Data
No Data available this quarter, please select a different quarter.
2.45%
Operating income growth while CRVO declines. John Neff would investigate advantages.
No Data
No Data available this quarter, please select a different quarter.
49.45%
Other expenses growth while CRVO reduces costs. John Neff would investigate differences.
10.71%
Pre-tax income growth while CRVO declines. John Neff would investigate advantages.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
10.71%
Net income growth while CRVO declines. John Neff would investigate advantages.
No Data
No Data available this quarter, please select a different quarter.
23.59%
EPS growth while CRVO declines. John Neff would investigate advantages.
23.59%
Diluted EPS growth while CRVO declines. John Neff would investigate advantages.
16.70%
Share count reduction below 50% of CRVO's 2.84%. Michael Burry would check for concerns.
16.70%
Diluted share reduction below 50% of CRVO's 2.84%. Michael Burry would check for concerns.